Literature DB >> 2295858

Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus.

R S Schwalbe1, W J Ritz, P R Verma, E A Barranco, P H Gilligan.   

Abstract

Killing curves were used to characterize Staphylococcus haemolyticus isolates previously reported to contain subpopulations showing increased resistance to vancomycin. Results suggested that vancomycin and teicoplanin were ineffective at a concentration of 8 micrograms/ml and growth was seen between 24 and 48 h. Conversely, the lipopeptide antibiotic daptomycin at the same concentration rapidly killed tested strains by 6 h. Various staphylococcal strains were examined to determine if vancomycin resistance could be selected in all strains of staphylococci, was specie(s) restricted, or was unique to this patient's clinical isolates. About 1 x 10(8) colony-forming units were added to melted brain-heart infusion agar plates containing 12 micrograms/ml of vancomycin. Plates were examined after 48 h for presence of resistant clones. Results indicated that selection for vancomycin resistance was restricted to S. haemolyticus strains. Further, all S. haemolyticus isolates that displayed a double zone of growth around imipenem agar diffusion discs (Impdz) contained stably resistant subpopulations. Vancomycin resistance could not be selected in imipenem-sensitive derivative clones. Impdz isolates that were recovered from geographically distinct locations displayed nearly identical SDS-PAGE protein profiles. It appears that a characteristic susceptibility pattern displayed by clinical isolates of S. haemolyticus may provide a marker for those strains that contain subpopulations having increased resistance to vancomycin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295858     DOI: 10.1093/infdis/161.1.45

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.

Authors:  F Biavasco; R Lupidi; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis.

Authors:  L Herwaldt; L Boyken; M Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

3.  Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci.

Authors:  K Sieradzki; P Villari; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

Authors:  R S Schwalbe; A C McIntosh; S Qaiyumi; J A Johnson; R J Johnson; K M Furness; W J Holloway; L Steele-Moore
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Increased resistance among Staphylococcus epidermidis isolates in a large teaching hospital over a 12-year period.

Authors:  O Lyytikäinen; M Vaara; E Järviluoma; K Rosenqvist; L Tiittanen; V Valtonen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-02       Impact factor: 3.267

6.  Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.

Authors:  B E Domaracki; A M Evans; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

7.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

8.  Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection.

Authors:  L A Veach; M A Pfaller; M Barrett; F P Koontz; R P Wenzel
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

9.  Linezolid Treatment for Osteomyelitis due to Staphylococcus Epidermidis with Reduced Vancomycin Susceptibility.

Authors:  Joon Rok Nam; Myoung Soo Kim; Chae Heuck Lee; Dong Hee Whang
Journal:  J Korean Neurosurg Soc       Date:  2008-06-20

Review 10.  Vancomycin resistance in staphylococci.

Authors:  Arjun Srinivasan; James D Dick; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.